Laekna's Obesity Drug Shows Promise in Early Stage Testing; Shares Fall 11%
MT Newswires Live
Yesterday
Laekna (HKG:2105) said early-stage low-dose testing of its obesity treatment candidate LAE102 was well tolerated and led to reductions in fat mass among participants, according to a Tuesday filing to the Hong Kong bourse.
The biotechnology company said the 24‑week study reported no serious adverse events and no cases of diarrhea, muscle spasms or acne.
Laekna said it plans to conduct high‑dose testing under similar conditions and is seeking partners to accelerate the treatment's development and commercialization.
Shares were last down 11% in afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.